110256-15-0

Basic information

• Product Name: 5-CYCLOPROPYLISOXAZOLE-3-CARBOXYLIC ACI&
• Synonyms: 5-CYCLOPROPYLISOXAZOLE-3-CARBOXYLIC ACI&;3-Isoxazolecarboxylicacid,5-cyclopropyl-(9CI);5-cyclopropylisoxazole-3-carboxylic acid(SALTDATA: FREE);3-Isoxazolecarboxylicacid, 5-cyclopropyl-;5-cyclopropyl-3-isoxazolecarboxylic acid
• CAS NO: 110256-15-0
• Molecular Formula: C₇H₇NO₃
• Molecular Weight: 153.136
• Product Categories: OXAZOLE;GLYCINESCAFFOLD;CARBOXYLICACID;Building Blocks;Heterocyclic Building Blocks;Isoxazoles;Building Blocks;Chemical Synthesis;Heterocyclic Building Blocks
• Mol File: 110256-15-0.mol

Chemical Properties

• Melting Point: 96-100 °C(lit.)
• Boiling Point: 358.1°C at 760 mmHg
• Flash Point: 170.4°C
• Appearance: /
• Density: 1.445
• Vapor Pressure: 9.48E-06mmHg at 25°C
• Refractive Index: 1.586
• Storage Temp.: Sealed in dry,Store in freezer, under -20°C
• PKA: 3.46±0.10(Predicted)
• CAS DataBase Reference: 5-CYCLOPROPYLISOXAZOLE-3-CARBOXYLIC ACI&(CAS DataBase Reference)
• NIST Chemistry Reference: 5-CYCLOPROPYLISOXAZOLE-3-CARBOXYLIC ACI&(110256-15-0)
• EPA Substance Registry System: 5-CYCLOPROPYLISOXAZOLE-3-CARBOXYLIC ACI&(110256-15-0)

Safety Data

• Hazard Codes: Xn
• Statements: 22
• WGK Germany: 3
• Hazardous Substances Data: 110256-15-0(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Research and Development:
5-Cyclopropylisoxazole-3-carboxylic Acid is utilized as a building block in the discovery, design, and synthesis of a selective S1P3 receptor allosteric agonist, specifically N,N-Dicyclohexyl-5-propylisoxazole-3-carboxamide. This agonist has potential applications in the treatment of various diseases and conditions by modulating the activity of the S1P3 receptor, which plays a crucial role in cellular processes.
Used in Drug Discovery:
In the pharmaceutical industry, 5-Cyclopropylisoxazole-3-carboxylic Acid serves as a valuable intermediate for the development of new drugs targeting the S1P3 receptor. Its unique structure allows for the fine-tuning of drug candidates to achieve optimal selectivity, potency, and efficacy.
Used in Medicinal Chemistry:
5-Cyclopropylisoxazole-3-carboxylic Acid is employed as a versatile synthetic precursor in medicinal chemistry. Its reactivity and structural features make it suitable for the creation of diverse chemical libraries, which can be screened for potential therapeutic agents with improved pharmacological properties.
Used in Chemical Synthesis:
Beyond its direct application in drug discovery, 5-Cyclopropylisoxazole-3-carboxylic Acid is also used in the broader field of chemical synthesis. Its carboxylic acid group can be used to form various derivatives, expanding the scope of its potential applications in different industries, including materials science and agrochemicals.

InChI:InChI=1/C7H7NO3/c9-7(10)5-3-6(11-8-5)4-1-2-4/h3-4H,1-2H2,(H,9,10)

Upstream product

• 6746-94-7 Cyclopropylacetylene 
• 21080-80-8 ethyl 4-cyclopropyl-2,4-dioxobutanoate 
• 1354822-96-0 ethyl (3Z)-4-cyclopropyl-4-hydroxy-2-oxo-3-butenoate 
• 21080-81-9 ethyl 5-cyclopropylisoxazole-3-carboxylate 
• 765-43-5 Cyclopropyl methyl ketone 

Relevant articles and documents

A Pyrazolo[3,4-D]pyrimidin-4-amine Derivative Containing an Isoxazole Moiety Is a Selective and Potent Inhibitor of RET Gatekeeper Mutants

Aberrant RET kinase signaling plays critical roles in several human cancers such as thyroid carcinoma. The gatekeeper mutants (V804L or V804M) of RET are resistant to currently approved RET inhibitors such as cabozantinib and vandetanib. We, for the first time, report a highly selective and extremely potent RET inhibitor, 6i rationally designed. Compound 6i inhibits strongly RET gatekeeper mutants and other clinically relevant RET mutants as well as wt-RET. This substance also significantly suppresses growth of thyroid cancer-derived TT cell lines and Ba/F3 cells transformed with various RET mutants. Docking studies reveal that the isoxazole moiety in 6i is responsible for binding affinity improvement by providing additional site for H-bonding with Lys758. Also, 6i not only substantially blocks cellular RET autophosphorylation and its downstream pathway, it markedly induces apoptosis and anchorage-independent growth inhibition in TT cell lines while having no effect on normal thyroid Nthy ori-3-1 cells.

Substituted Cyclohexylamine Compounds

The present disclosure provides substituted cyclohexylamine compounds having Formula (I): and the pharmaceutically acceptable salts and solvates thereof, wherein R1, R2a, R2b, R3a, R3b, R4, R5, and R7 are defined as set forth in the specification. The present disclosure is also directed to the use of compounds of Formula I to treat a disorder responsive to the blockade of SMYD proteins such as SMYD3 or SMYD2. Compounds of the present disclosure are especially useful for treating cancer.

SUBSTITUTED CYCLOHEXYLAMINE COMPOUNDS

The present disclosure provides substituted cyclohexylamine compounds having Formula (I): and the pharmaceutically acceptable salts and solvates thereof, wherein R1, R2a, R2b, R3a, R3b, R4, R5, and R7 are defined as set forth in the specification. The present disclosure is also directed to the use of compounds of Formula I to treat a disorder responsive to the blockade of SMYD proteins such as SMYD3 or SMYD2. Compounds of the present disclosure are especially useful for treating cancer.

SUBSTITUTED PYRROLIDINE COMPOUNDS

The present disclosure provides substituted pyrrolidine compounds having Formula (I): and the pharmaceutically acceptable salts and solvates thereof, wherein R1, B, X, and Z are defined as set forth in the specification. The present disclosure is also directed to the use of compounds of Formula (I) to treat a disorder responsive to the blockade of SMYD proteins such as SMYD3 or SMYD2. Compounds of the present disclosure are especially useful for treating cancer.

ISOXAZOLE CARBOXAMIDE COMPOUNDS

The present disclosure provides substituted isoxazole carboxamide compounds having Formula (I) and the pharmaceutically acceptable salts and solvates thereof, wherein R1, R2, A, X, and Z are defined as set forth in the specification. The present disclosure is also directed to the use of compounds of Formula I to treat a disorder responsive to the blockade of SMYD proteins such as SMYD3 or SMYD2. Compounds of the present disclosure are especially useful for treating cancer.

ISOXAZOLE CARBOXAMIDES AS IRREVERSIBLE SMYD INHIBITORS

The present disclosure provides provides substituted isoxazole carboxamides having Formula (I), and the pharmaceutically acceptable salts and solvates thereof, wherein R1, R2a, R2b, R3a, R3b, X, n, and m are defined as set forth in the specification. The present disclosure is also directed to the use of compounds of Formula I to treat a disorder responsive to the blockade of SMYD proteins such as SMYD3 or SMYD2. Compounds of the present disclosure are especially useful for treating cancer.

SUBSTITUTED PIPERIDINE COMPOUNDS

The present disclosure provides substituted piperidine compounds having Formula (I), and the pharmaceutically acceptable salts and solvates thereof, wherein R1, B, X, and Z are defined as set forth in the specification. The present disclosure i

INDOLE AMIDE DERIVATIVES AND RELATED COMPOUNDS FOR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES

This invention provides novel compounds and the novel compounds for use as a medicine, more in particular for the prevention or treatment of neurodegenerative disorders, more specifically certain neurological disorders, such as disorders collectively known as tauopathies, and disorders characterised by cytotoxic α-synuclein amyloidogenesis. The present invention also relates to the use of said novel compounds for the manufacture of medicaments useful for treating such neurodegenerative disorders. The present invention further relates to pharmaceutical compositions including said novel compounds and to methods for the preparation of said novel compounds.

Positive allosteric modulators of the nicotinic acetylcholine receptor

The invention provides compounds of Formula I: These compounds may be in the form of pharmaceutical salts or compositions, may be in pure enantiomeric form or racemic mixtures, and are useful in pharmaceuticals used to treat diseases or conditions in which α7 nAChR is known to be involved.

Isoxazole derivatives

Isoxazole derivatives represented by the formula: STR1 are prepared; wherein R1 and R2 each is hydrogen atom, alkyl group of 1 to 8 carbon atoms, or cycloalkyl group of 3 to 10 carbon atoms; R3 and R4 each is hydrogen atom, alkyl group of 1 to 8 carbon atoms, cycloalkyl group of 3 to 10 carbon atoms, or phenyl group; or the group Is morpholino group; and Y is oxo group, thioxo group or imino group; being useful as a hypoglycemic and/or a blood free-fatty-acid normalizing antidiabetic agent.